216 related articles for article (PubMed ID: 10629244)
1. Pharmacokinetics and pharmacodynamics of moist snuff in humans.
Fant RV; Henningfield JE; Nelson RA; Pickworth WB
Tob Control; 1999; 8(4):387-92. PubMed ID: 10629244
[TBL] [Abstract][Full Text] [Related]
2. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines.
Hoffmann D; Djordjevic MV; Fan J; Zang E; Glynn T; Connolly GN
J Natl Cancer Inst; 1995 Dec; 87(24):1862-9. PubMed ID: 7494230
[TBL] [Abstract][Full Text] [Related]
3. The relative buffering capacities of saliva and moist snuff: implications for nicotine absorption.
Ciolino LA; McCauley HA; Fraser DB; Wolnik KA
J Anal Toxicol; 2001; 25(1):15-25. PubMed ID: 11215994
[TBL] [Abstract][Full Text] [Related]
4. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum.
Benowitz NL; Porchet H; Sheiner L; Jacob P
Clin Pharmacol Ther; 1988 Jul; 44(1):23-8. PubMed ID: 3391001
[TBL] [Abstract][Full Text] [Related]
5. In vitro study of nicotine release from smokeless tobacco.
Nasr MM; Reepmeyer JC; Tang Y
J AOAC Int; 1998; 81(3):540-3. PubMed ID: 9606918
[TBL] [Abstract][Full Text] [Related]
6. Nicotine intake and dependence in Swedish snuff takers.
Holm H; Jarvis MJ; Russell MA; Feyerabend C
Psychopharmacology (Berl); 1992; 108(4):507-11. PubMed ID: 1410167
[TBL] [Abstract][Full Text] [Related]
7. Daily use of smokeless tobacco: systemic effects.
Benowitz NL; Jacob P; Yu L
Ann Intern Med; 1989 Jul; 111(2):112-6. PubMed ID: 2742246
[TBL] [Abstract][Full Text] [Related]
8. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge.
Kotlyar M; Mendoza-Baumgart MI; Li ZZ; Pentel PR; Barnett BC; Feuer RM; Smith EA; Hatsukami DK
Tob Control; 2007 Apr; 16(2):138-42. PubMed ID: 17400953
[TBL] [Abstract][Full Text] [Related]
9. Determination of nicotine, pH, and moisture content of six U.S. commercial moist snuff products--Florida, January-February 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 May; 48(19):398-401. PubMed ID: 10366135
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff.
Lunell E; Fagerström K; Hughes J; Pendrill R
Nicotine Tob Res; 2020 Oct; 22(10):1757-1763. PubMed ID: 32319528
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of moist snuff: total nicotine, moisture, pH, un-ionized nicotine, and tobacco-specific nitrosamines.
Richter P; Hodge K; Stanfill S; Zhang L; Watson C
Nicotine Tob Res; 2008 Nov; 10(11):1645-52. PubMed ID: 18988077
[TBL] [Abstract][Full Text] [Related]
12. Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000-2006.
Alpert HR; Koh H; Connolly GN
Tob Control; 2008 Oct; 17(5):332-8. PubMed ID: 18669556
[TBL] [Abstract][Full Text] [Related]
13. Effects of treatment on cardiovascular risk among smokeless tobacco users.
Allen SS; Hatsukami D; Jensen J; Grillo M; Bliss R
Prev Med; 1995 Jul; 24(4):357-62. PubMed ID: 7479625
[TBL] [Abstract][Full Text] [Related]
14. Treatment of spit tobacco users with transdermal nicotine system and mint snuff.
Hatsukami DK; Grillo M; Boyle R; Allen S; Jensen J; Bliss R; Brown S
J Consult Clin Psychol; 2000 Apr; 68(2):241-9. PubMed ID: 10780124
[TBL] [Abstract][Full Text] [Related]
15. Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users.
Gritz ER; Baer-Weiss V; Benowitz NL; Van Vunakis H; Jarvik ME
Clin Pharmacol Ther; 1981 Aug; 30(2):201-9. PubMed ID: 7195786
[TBL] [Abstract][Full Text] [Related]
16. Comparison of blood aldehyde dehydrogenase activities in moist snuff users, cigarette smokers and nontobacco users.
Helander A; Curvall M
Alcohol Clin Exp Res; 1991 Feb; 15(1):1-6. PubMed ID: 2024719
[TBL] [Abstract][Full Text] [Related]
17. Nicotine intake by snuff users.
Russell MA; Jarvis MJ; Devitt G; Feyerabend C
Br Med J (Clin Res Ed); 1981 Sep; 283(6295):814-7. PubMed ID: 6794710
[TBL] [Abstract][Full Text] [Related]
18. Review of the evidence that pH is a determinant of nicotine dosage from oral use of smokeless tobacco.
Tomar SL; Henningfield JE
Tob Control; 1997; 6(3):219-25. PubMed ID: 9396107
[TBL] [Abstract][Full Text] [Related]
19. The pH of Smokeless Tobacco Determines Nicotine Buccal Absorption: Results of a Randomized Crossover Trial.
Wilhelm J; Mishina E; Viray L; Paredes A; Pickworth WB
Clin Pharmacol Ther; 2022 May; 111(5):1066-1074. PubMed ID: 34826137
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
